These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

501 related items for PubMed ID: 7111040

  • 1. [Chelating therapy in beta-thalassemia].
    Musumeci S, Romeo MA, Di Gregorio F, Schiliró G, Russo G.
    Pediatr Med Chir; 1982; 4(1-2):55-9. PubMed ID: 7111040
    [Abstract] [Full Text] [Related]

  • 2. Iron metabolism in thalassemia intermedia.
    Fiorelli G, Fargion S, Piperno A, Battafarano N, Cappellini MD.
    Haematologica; 1990; 75 Suppl 5():89-95. PubMed ID: 2086386
    [Abstract] [Full Text] [Related]

  • 3. Desferrioxamine induced urinary iron excretion in thalassemia.
    Dubey AP, Kumar S, Choudhury P, Talukdar B, Puri RK.
    Indian Pediatr; 1993 Jun; 30(6):775-8. PubMed ID: 8132258
    [Abstract] [Full Text] [Related]

  • 4. Advances in the use of iron-chelating agents for the treatment of iron overload.
    Modell B.
    Prog Hematol; 1979 Jun; 11():267-312. PubMed ID: 392593
    [No Abstract] [Full Text] [Related]

  • 5. [Effect of two years of deferoxamine therapy on iron balance, ferritin, liver and heart in patients with thalassemia major].
    Flückiger A, Imbach P, Pfenninger E, Stocker F, Töndury P, Wagner HP, Weber J, Zuppinger K.
    Helv Paediatr Acta; 1985 Sep; 40(4):293-304. PubMed ID: 4077563
    [Abstract] [Full Text] [Related]

  • 6. Iron overload and desferrioxamine chelation therapy in beta-thalassemia intermedia.
    Cossu P, Toccafondi C, Vardeu F, Sanna G, Frau F, Lobrano R, Cornacchia G, Nucaro A, Bertolino F, Loi A, De Virgiliis S, Cao A.
    Eur J Pediatr; 1981 Nov; 137(3):267-71. PubMed ID: 7318837
    [Abstract] [Full Text] [Related]

  • 7. Chelation therapy in beta-thalassemia: the benefits and limitations of desferrioxamine.
    Giardina PJ, Grady RW.
    Semin Hematol; 1995 Oct; 32(4):304-12. PubMed ID: 8560288
    [Abstract] [Full Text] [Related]

  • 8. Chelation therapy and ferritin levels in patients with homozygous beta-thalassemia.
    Kattamis C, Lagos P, Langona E.
    Prog Clin Biol Res; 1979 Oct; 34():351-9. PubMed ID: 531060
    [No Abstract] [Full Text] [Related]

  • 9. [The echocardiography in thalassemia major (author's transl)].
    Musumeci S, Schiliro G, Romeo MA, Di Gregorio F, Russo G, Scibilia G.
    Pediatr Med Chir; 1981 Oct; 3(2-3):219-22. PubMed ID: 6211659
    [Abstract] [Full Text] [Related]

  • 10. Reduction of iron overload in thalassemia.
    Piomelli S, Graziano J.
    Birth Defects Orig Artic Ser; 1982 Oct; 18(7):339-46. PubMed ID: 7159742
    [No Abstract] [Full Text] [Related]

  • 11. Clinical management of beta-thalassemia.
    Graziano J, Piomelli S.
    Tex Rep Biol Med; 1982 Oct; 40():355-64. PubMed ID: 7034276
    [No Abstract] [Full Text] [Related]

  • 12. Medical management of beta-thalassemia.
    Lerner N.
    Prog Clin Biol Res; 1989 Oct; 309():13-22. PubMed ID: 2780747
    [No Abstract] [Full Text] [Related]

  • 13. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States.
    Delea TE, Hagiwara M, Thomas SK, Baladi JF, Phatak PD, Coates TD.
    Am J Hematol; 2008 Apr; 83(4):263-70. PubMed ID: 17924547
    [Abstract] [Full Text] [Related]

  • 14. [Nuclear magnetic resonance and iron overload in thalassemia].
    Schettini F, De Mattia D, Cavallo L, Sabato V, Santoro N, Del Vecchio GC, Martinelli G, Martinelli A, Di Bartolomeo P, Di Girolamo G.
    Minerva Pediatr; 1991 Dec; 43(12):777-81. PubMed ID: 1798402
    [Abstract] [Full Text] [Related]

  • 15. Quality of life in transfusion-dependent thalassaemia patients on desferrioxamine treatment.
    Dahlui M, Hishamshah MI, Rahman AJ, Aljunid SM.
    Singapore Med J; 2009 Aug; 50(8):794-9. PubMed ID: 19710979
    [Abstract] [Full Text] [Related]

  • 16. [Beta-pancreatic function in subjects with thalassemia. A 4-year follow-up].
    Zanini R, Briante G, Cantone P, Sticca M, Grasso U.
    Pediatr Med Chir; 1985 Aug; 7(5):749-53. PubMed ID: 3915549
    [Abstract] [Full Text] [Related]

  • 17. [Evaluation of iron overload in thalassemia].
    Piga A, Davico S, Magliano M, Luzzatto L, Sandri A, Gabutti V.
    Pediatr Med Chir; 1986 Aug; 8(1):9-13. PubMed ID: 3725619
    [Abstract] [Full Text] [Related]

  • 18. [Evaluation of iron balance in homozygous beta-thalassemia subjects treated with desferrioxamine administered subcutaneously].
    Ferrara M, Galdo Capotorti M, Ponte G, Esposito L.
    Pediatria (Napoli); 1983 Aug; 91(4):371-7. PubMed ID: 6545400
    [No Abstract] [Full Text] [Related]

  • 19. Reassessment of the use of desferrioxamine B in iron overload.
    Propper RD, Shurin SB, Nathan DG.
    N Engl J Med; 1976 Jun 24; 294(26):1421-3. PubMed ID: 1272274
    [Abstract] [Full Text] [Related]

  • 20. [Thalassemia major: chelating therapy with deferoxamine].
    Abreu de Miani MS, Sanchis de Herrlein MS, Peñalver JA.
    Medicina (B Aires); 1985 Jun 24; 45(3):231-4. PubMed ID: 3841934
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.